Hepatorenal syndrome
Tóm tắt
The management of the hepatorenal syndrome (HRS) constitutes a major challenge for clinicians. Because HRS is a functional disorder due to advanced liver disease and is associated with a very low survival expectancy, orthotopic liver transplantation (OLT) is the only effective and permanent treatment for patients with HRS. However, OLT is not applicable to all cirrhotic patients despite the presence of HRS. In addition, because of the poor prognosis of HRS and the prolonged waiting lists in most transplant centers a significant proportion of these patients may die before OLT is possible. Therefore, there is a need for effective therapies for HRS that improve renal function and increase survival. Such treatments are of interest not only as a bridge to OLT but also as a therapy for patients who are not candidates for transplantation. Preliminary studies have suggested that the administration of splanchnic vasoconstrictors such as terlipressin in combination with volume expanders or the insertion of transjugular intrahepatic portosystemic shunts (TIPS) may improve renal function in patients with HRS. However, before these treatments are widely recommended further studies are necessary.
Tài liệu tham khảo
Arroyo V, Bataller R: Historical notes on ascites in cirrosis. In Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Edited by Arroyo V, Ginès P, Rodés J, et al. Boston: Blackwell Science Inc.; 1999:3–13.
Arroyo V, Ginès P, Gerbes A, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome. Hepatology 1996, 23:164–167. Review and definitions from the Consensus Conference of the International Ascites Club.
Epstein M, Berk DP, Hollenberg NK, et al.: Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med 1970, 49:175–185.
Moore K: The hepatorenal syndrome. Clin Sci 1997, 92:433–443.
Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151–1157. Paper with the description of the arterial vasodilation theory, which best explains the development of HRS.
Martin PY, Ginès P, Schrier RW: Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339:533–541. The role of nitric oxide in hemodynamic abnormalities of cirrhosis is reviewed.
Ginès A, Escorsell A, Ginès P, et al.: Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993, 105:229–236.
Gonwa TA, Klintmalm GB, Levy M, et al.: Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995, 59:361–365.
Guevara M, Ginès P, Fernández-Esparrach G, et al.: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27:35–41.
Gülber V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal síndrome type I with ornipressin and dopamine. Hepatology 1999, 30:870–875.
Glycylpressin R, Terlipressin Acetate. In Fachinformation. Kiel, Austria: Ferring Arzneimittel GmbH; 1996.
Uriz J, Ginès P, Cárdenas A, et al.: Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000, 33:43–48. A pilot study reporting the reversal of hepatorenal syndrome in 78% of the patients assessed.
Shiffman ML, Jeffers L, Hoofnagle JH, et al.: The role of transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Disease advisory board. Hepatology 1995, 25:1591–1597.
Ochs A, Rössle M, Haag K, et al.: The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med 1995, 332:1192–1197.
Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome. Hepatology 1998, 27:35–41.
Brensing KA, Textor J, Strunk H, et al.: Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997, 349:697–698.
Angeli P, Volpin R, Gerunda G, et al.: Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatolgy 1999, 29:1690–1697.
Fevery J, Van Custem E, Nevens F, et al.: Reversal of hepatorenal sybdrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin admnistration. J Hepatol 1990, 11:153–158.
Ginès A, Salmerón JM, Ginès P, et al.: Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993, 17:220–226.
Arroyo V, Bataller R, Guevara M: Treatment of hepatorenal syndrome in cirrhosis. In Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Edited by Arroyo V, Ginès P, Rodés J, et al. Boston: Blackwell Science Inc.; 1999:492–510.